pimavanserin

A 5-HT(2A) inverse agonist; ACP-103 is the dihydroxybutanedioate (2:1) salt. It is used to treat hallucinations and delusions associated with PARKINSON DISEASE; structure in first source.

Also Known As:

ACP 103; ACP-103; ACP103; N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide; Nuplazid; bis(1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioate; pimavanserin tartrate; urea, n-((4-fluorophenyl)methyl)-n-(1-methyl-4-piperidinyl)-n'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)

Networked: 216 relevant articles (51 outcomes, 46 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Stankovic, Srdjan: 14 articles (12/2023 - 01/2018)
2.	Ballard, Clive: 13 articles (04/2024 - 02/2014)
3.	Coate, Bruce: 11 articles (01/2024 - 10/2015)
4.	Abler, Victor: 8 articles (01/2024 - 01/2020)
5.	Friedman, Joseph H: 8 articles (01/2022 - 03/2010)
6.	Weintraub, Daniel: 7 articles (12/2023 - 02/2017)
7.	Norton, James C: 7 articles (03/2022 - 04/2017)
8.	DeKarske, Daryl: 6 articles (01/2024 - 01/2020)
9.	Doshi, Dilesh: 6 articles (01/2024 - 01/2022)
10.	Rajagopalan, Krithika: 6 articles (01/2024 - 10/2022)

Related Diseases

1.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2022 - "There was a significant improvement in psychosis symptoms in patients with PD who took pimavanserin. " 01/01/2020 - "Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD." 07/28/2019 - "Pimavanserin at 34 mg daily was shown to be effective for PD-induced psychosis in past clinical trials." 09/30/2023 - "It is possible that pimavanserin may also be useful in the treatment of psychosis in DLB. " 03/01/2014 - "Though not currently available, the novel 5-HT2a inverse agonist, pimavanserin has shown promise in the treatment of PD psychosis. "
2.	Parkinson Disease (Parkinson's Disease) 01/01/2018 - "Patients in the pimavanserin group experienced a significant (p=0.001) improvement in Scale for the Assessment of Positive Symptoms - Parkinson's disease (SAPS-PD) scores vs. placebo. " 01/01/2020 - "An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson's Disease and Depression." 09/01/2017 - "Pimavanserin has demonstrated no worsening of motor symptoms of Parkinson disease, but only 1 of 4 trials has shown consistent statistically significant improvements in psychotic symptoms compared with placebo. " 03/01/2022 - "Pimavanserin initiators were younger and had fewer severe comorbidities, indicators of impairment, and healthcare encounters, though they had higher Parkinson's disease medication use. " 01/01/2022 - "Author Response: Risk of Hospitalization and Death Associated With Pimavanserin Use in Older Adults With Parkinson Disease."
3.	Hallucinations (Hallucination) 01/01/2022 - "Treatment with pimavanserin was associated with a significant reduction in scores using the Scale of Assessment of Positive Symptoms, Hallucinations, and Delusion (SAPS-H+D) (mean difference [MD]: -1.55 [-2.71, -0.379], p=0.009). " 01/01/2022 - "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." 04/09/2024 - "Our analysis of nine sponsored CME activities reveals misleading themes, including: PDP is common, progressive, and not always drug-induced; there is no such thing as a benign hallucination, and psychotic symptoms always worsen; PDP increases mortality; and competing treatments are ineffective or dangerous while pimavanserin is safe and effective for treating PDP. " 10/25/2022 - "Further, re-initiation of Pimavanserin helped treat his hallucinations. " 01/01/2024 - "This trial evaluated the effects of pimavanserin compared to placebo in frail older adults and elderly patients with neuropsychiatric symptoms related to NDD, such as hallucinations and delusions, to better understand the safety of pimavanserin in this population. "
4.	Alzheimer Disease (Alzheimer's Disease) 01/01/2021 - "These data demonstrate that Pimavanserin may have disease-modifying benefits in addition to its efficacy against neuropsychiatric symptoms of Alzheimer's disease. " 01/01/2022 - "The impact of pimavanserin on psychotic phenotypes and tau phosphorylation in the P301L/COMT- and rTg(P301L)4510 mouse models of Alzheimer's disease." 01/01/2021 - "Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease." 01/01/2018 - "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0.045) improved psychosis at Week 6 vs. placebo on the NPI-NH Psychosis Score (PS). " 11/01/2020 - "Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis."
5.	Dementia (Dementias) 01/01/2021 - "Issues addressed include distinguishing PDP from similar symptoms caused by other disorders such as dementia, coordinating pimavanserin with other PD medications and with deep brain stimulation, adapting pimavanserin dosing for optimal benefit and tolerability, and recognizing variability of PDP symptoms due to patients' changing life circumstances. " 02/01/2024 - "This subgroup analysis included PDD patients enrolled in an international, multicenter, randomized discontinuation study of pimavanserin for dementia-related psychosis. " 02/01/2024 - "We analyzed the effect of pimavanserin on psychosis in the PD dementia (PDD) subgroup from the phase 3 HARMONY trial. " 09/01/2021 - " opinion: Two controlled studies suggest pimavanserin has potential as a treatment for hallucinations in dementia. " 01/01/2021 - "Longer and larger trials are required to determine the effects of pimavanserin in dementia-related psychosis. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Clozapine (Clozaril)
3.	5-HT2A Serotonin Receptor (5 HT2A Receptor)
4.	Serotonin (5 Hydroxytryptamine)
5.	pimavanserin
6.	Cholinesterase Inhibitors (Anticholinesterases)
7.	Levodopa (L Dopa)
8.	Antidepressive Agents (Antidepressants)
9.	Lithium
10.	Escitalopram

Related Therapies and Procedures

1.	Therapeutics
2.	Long-Term Care
3.	Deep Brain Stimulation
4.	Secondary Prevention
5.	Activities of Daily Living (ADL)